ANDA Sponsors Given More Paperwork, But New Cover Letter Could Actually Be A Time-Saver
Executive Summary
Optional checklists will help ensure submissions have all the required information.
You may also be interested in...
Growing Complex Generic Application Load May Force US FDA Staffing Changes
Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.
GDUFA III: Convening Enhanced Mid-Cycle Meeting Will Cost Sponsors
Requesting the new meeting type for an ANDA assessment will trigger a goal date extension with another possible should an unsolicited application amendment also be necessary.
US FDA Preparing For Potential Bolus Of Complex Generic Applications
Increasing number of product development meetings suggests that many complex generics remain in the development stages.